500672 — Novartis India Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹29.06bn
- IN₹23.16bn
- IN₹3.35bn
- 48
- 23
- 86
- 52
Annual cashflow statement for Novartis India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 286 | 400 | -38.2 | 1,154 | 1,228 |
| Depreciation | |||||
| Non-Cash Items | -249 | -171 | -153 | -550 | -594 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -400 | -1,043 | 481 | -217 | 473 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -231 | -692 | 387 | 448 | 1,134 |
| Capital Expenditures | -10 | -0.9 | -5 | -3.1 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 569 | 953 | 875 | -1,529 | 331 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 559 | 952 | 870 | -1,533 | 331 |
| Financing Cash Flow Items | -115 | -65.4 | -0.4 | -0.5 | -0.1 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -414 | -368 | -356 | -305 | -1,210 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -86.4 | -109 | 901 | -1,389 | 255 |